Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures

PHASE2CompletedINTERVENTIONAL
Enrollment

222

Participants

Timeline

Start Date

July 6, 2011

Primary Completion Date

June 30, 2013

Study Completion Date

January 28, 2021

Conditions
Partial Epilepsy
Interventions
DRUG

YKP3089

Capsule, dose to be titrated Tablet, dose to be titrated

DRUG

Placebo

Placebo capsule Placebo tablet

Trial Locations (38)

19104

University of Pennsylvania Health System, Philadelphia

19107

Thomas Jefferson University Comprehensive Epilepsy Center, Philadelphia

20817

Mid-Atlantic Epilepsy and Sleep Center, Bethesda

21287

John's Hopkins University School of Medicine, Baltimore

22903

University of Virginia, Charlottesville

34205

Bradenton Research Center, Inc., Bradenton

40504

Bluegrass Epilepsy Research, LLC, Lexington

43210

Ohio State University Medical Center, Columbus

43614

The University of Toledo, Toledo

63017

Suite 209 South, Chesterfield

72205

Clinical Trials, Inc., Little Rock

73112

Lynn Health Science Institute, Oklahoma City

75230

Neurological Clinic of Texas, P.A., Dallas

85013

St. Joseph Hospital & Medical Center/Barrow Neurology Clinic, Phoenix

90073

VA Greater Los Angeles Healthcare System, Los Angeles

92806

Kaiser Permanente, Anaheim

411004

Deenanath Mangeshkar Hospital & Research Centre, Pune

560043

Bangalore Clinisearch, Bangalore

500 018

St. Theresa's General Hospital, Hyderabad

560 054

M.S. Ramaiah Medical College and Hospital, Bangalore

575 002

Mallikatta Neuro Centre, Mangalore

110 017

Max Super Specialty Hospital, Saket

700 071

Nightingale Hospital, Kolkata

44-100

NZOZ Vito-Med Sp. Zo.o, Gliwice

40-594

NZOZ Diagnomed, Katowice

40-635

SPSK Nr 7 SUM w Katowicach, Gornoslaskie CM im. Prof. Leszka Gieca, Katowice

30-510

Malopolskie Centrum Medyczne, Krakow

31-209

Centrum Leczenia Padaczki i Migreny, Krakow

90-242

Centrum Terapii Wspolczesnej, Lodz

60-539

Solumed s.c., Poznan

602-715

Dong-A University Medical Center, Busan

700-712

Keimyung University Dongsan Hospital, Daegu

301-721

Chungnam National University Hospital, Daejeon

431-070

Hallym University Sacred Heart Hospital, Gyeonggi-do

110-744

Seoul National University Hospital, Seoul

135-710

Samsung Medical Center, Seoul

136-705

Korea University Anam Hospital, Seoul

138-736

Asan Medical Center, Seoul

All Listed Sponsors
lead

SK Life Science, Inc.

INDUSTRY

NCT01397968 - Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures | Biotech Hunter | Biotech Hunter